Jui-Hua Tsai, Norah L Crossnohere, Theresa Strong, John F P Bridges
{"title":"衡量有意义的利益-风险权衡以促进以患者为中心的药物开发:一个离散选择实验。","authors":"Jui-Hua Tsai, Norah L Crossnohere, Theresa Strong, John F P Bridges","doi":"10.1177/23814683211039457","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background.</b> Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder causing quality of life impairments such as insatiable hunger (hyperphagia) and obesity. We explored caregivers' willingness to assume treatment risk in exchange for reduced hyperphagia according to a PWS-validated observer-reported outcome measure. <b>Methods.</b> We partnered with PWS patient organizations to develop a discrete-choice experiment exploring caregivers' benefit-risk tradeoffs for emerging PWS treatments. The treatment benefit was a reduction in hyperphagia (as measured by a 0-, 5-, or 10-point change on the Hyperphagia Questionnaire for Clinical Trials [HQ-CT]). Treatment risks included weight gain (none, 5%, 10%), added risk of skin rash (none, 10%, 20%), and risk of liver damage (none, 1 in 1000, 10 in 1000). Preference models were estimated using mixed logistic regression and maximum acceptable risk. We explored differences in preferences across familial caregivers of patients with and without hyperphagia. <b>Results.</b> Four hundred sixty-eight caregivers completed the online survey. The majority of caregivers reported that patients experienced hyperphagia (68%) and half of patients experienced obesity (52%). Caregivers of patients without hyperphagia were willing to accept greater weight gain (16.4% v. 8.1%, <i>P</i> = 0.004) and a higher risk of skin rash (11.7% v. 6.2% <i>P</i> = 0.008) as compared to caregivers of patients with hyperphagia. Caregivers of patients with hyperphagia would accept a higher risk of liver damage as compared to caregivers of patients without hyperphagia (11.9 out of 1000 v. 6.4 out of 1000, <i>P</i> = 0.04). <b>Conclusions.</b> This research demonstrates that caregivers are willing to accept risk in exchange for a five-point improvement on the HQ-CT, a smaller marginal improvement than had been previously classified as meaningful. Patient experience with hyperphagia is a modifier in how much risk caregivers will accept.</p>","PeriodicalId":520707,"journal":{"name":"MDM policy & practice","volume":" ","pages":"23814683211039457"},"PeriodicalIF":1.7000,"publicationDate":"2021-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/82/10.1177_23814683211039457.PMC8419554.pdf","citationCount":"5","resultStr":"{\"title\":\"Measuring Meaningful Benefit-Risk Tradeoffs to Promote Patient-Focused Drug Development in Prader-Willi Syndrome: A Discrete-Choice Experiment.\",\"authors\":\"Jui-Hua Tsai, Norah L Crossnohere, Theresa Strong, John F P Bridges\",\"doi\":\"10.1177/23814683211039457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background.</b> Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder causing quality of life impairments such as insatiable hunger (hyperphagia) and obesity. We explored caregivers' willingness to assume treatment risk in exchange for reduced hyperphagia according to a PWS-validated observer-reported outcome measure. <b>Methods.</b> We partnered with PWS patient organizations to develop a discrete-choice experiment exploring caregivers' benefit-risk tradeoffs for emerging PWS treatments. The treatment benefit was a reduction in hyperphagia (as measured by a 0-, 5-, or 10-point change on the Hyperphagia Questionnaire for Clinical Trials [HQ-CT]). Treatment risks included weight gain (none, 5%, 10%), added risk of skin rash (none, 10%, 20%), and risk of liver damage (none, 1 in 1000, 10 in 1000). Preference models were estimated using mixed logistic regression and maximum acceptable risk. We explored differences in preferences across familial caregivers of patients with and without hyperphagia. <b>Results.</b> Four hundred sixty-eight caregivers completed the online survey. The majority of caregivers reported that patients experienced hyperphagia (68%) and half of patients experienced obesity (52%). Caregivers of patients without hyperphagia were willing to accept greater weight gain (16.4% v. 8.1%, <i>P</i> = 0.004) and a higher risk of skin rash (11.7% v. 6.2% <i>P</i> = 0.008) as compared to caregivers of patients with hyperphagia. Caregivers of patients with hyperphagia would accept a higher risk of liver damage as compared to caregivers of patients without hyperphagia (11.9 out of 1000 v. 6.4 out of 1000, <i>P</i> = 0.04). <b>Conclusions.</b> This research demonstrates that caregivers are willing to accept risk in exchange for a five-point improvement on the HQ-CT, a smaller marginal improvement than had been previously classified as meaningful. Patient experience with hyperphagia is a modifier in how much risk caregivers will accept.</p>\",\"PeriodicalId\":520707,\"journal\":{\"name\":\"MDM policy & practice\",\"volume\":\" \",\"pages\":\"23814683211039457\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/82/10.1177_23814683211039457.PMC8419554.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MDM policy & practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/23814683211039457\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM policy & practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23814683211039457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
摘要
背景。普瑞德-威利综合征(PWS)是一种罕见的神经发育障碍,导致生活质量受损,如贪得无厌(嗜食)和肥胖。根据pws验证的观察者报告的结果测量,我们探讨了护理者承担治疗风险以换取减少贪食的意愿。方法。我们与PWS患者组织合作,开发了一个离散选择实验,探索护理人员对新兴PWS治疗的利益-风险权衡。治疗的好处是嗜食的减少(通过临床试验嗜食问卷[HQ-CT]的0分、5分或10分的变化来衡量)。治疗风险包括体重增加(无,5%,10%),增加皮疹风险(无,10%,20%)和肝损伤风险(无,千分之一,千分之一)。使用混合逻辑回归和最大可接受风险估计偏好模型。我们探讨了有和没有贪食症患者的家庭照顾者的偏好差异。结果。468名护理人员完成了在线调查。大多数护理人员报告说,患者出现了贪食(68%),一半的患者出现了肥胖(52%)。与有贪食的患者相比,无贪食患者的护理人员愿意接受更大的体重增加(16.4% vs . 8.1%, P = 0.004)和更高的皮疹风险(11.7% vs . 6.2% P = 0.008)。与无贪食患者的护理人员相比,贪食患者的护理人员接受肝损伤的风险更高(11.9 / 1000 vs 6.4 / 1000, P = 0.04)。结论。这项研究表明,护理人员愿意接受风险,以换取红旗- ct的5分改善,这是一个比以前归类为有意义的更小的边际改善。患者对贪食症的经历是决定护理人员接受多少风险的一个因素。
Measuring Meaningful Benefit-Risk Tradeoffs to Promote Patient-Focused Drug Development in Prader-Willi Syndrome: A Discrete-Choice Experiment.
Background. Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder causing quality of life impairments such as insatiable hunger (hyperphagia) and obesity. We explored caregivers' willingness to assume treatment risk in exchange for reduced hyperphagia according to a PWS-validated observer-reported outcome measure. Methods. We partnered with PWS patient organizations to develop a discrete-choice experiment exploring caregivers' benefit-risk tradeoffs for emerging PWS treatments. The treatment benefit was a reduction in hyperphagia (as measured by a 0-, 5-, or 10-point change on the Hyperphagia Questionnaire for Clinical Trials [HQ-CT]). Treatment risks included weight gain (none, 5%, 10%), added risk of skin rash (none, 10%, 20%), and risk of liver damage (none, 1 in 1000, 10 in 1000). Preference models were estimated using mixed logistic regression and maximum acceptable risk. We explored differences in preferences across familial caregivers of patients with and without hyperphagia. Results. Four hundred sixty-eight caregivers completed the online survey. The majority of caregivers reported that patients experienced hyperphagia (68%) and half of patients experienced obesity (52%). Caregivers of patients without hyperphagia were willing to accept greater weight gain (16.4% v. 8.1%, P = 0.004) and a higher risk of skin rash (11.7% v. 6.2% P = 0.008) as compared to caregivers of patients with hyperphagia. Caregivers of patients with hyperphagia would accept a higher risk of liver damage as compared to caregivers of patients without hyperphagia (11.9 out of 1000 v. 6.4 out of 1000, P = 0.04). Conclusions. This research demonstrates that caregivers are willing to accept risk in exchange for a five-point improvement on the HQ-CT, a smaller marginal improvement than had been previously classified as meaningful. Patient experience with hyperphagia is a modifier in how much risk caregivers will accept.